Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Toma Biosciences

Explore full profile

Dna-based cancer testing technology the company was incorporated in 2011 and is based in

Foster City, United StatesFounded 2011Biotech & Life Sciences
Valuation $10–25M Last recorded · 2018
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Toma Biosciences and the history behind them.

At a glance

Founded
2011
Headquarters
Foster City, United States
Sector
Biotech & Life Sciences

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Keiretsu Forum

Series B and later7 investors entered at this stage

  • Prolog Ventures
  • SAYJ Global Partners
  • Correlation Ventures
  • Keiretsu Forum CEE
  • Keiretsu Capital
  • Paladin Capital Group
  • Vital Capital
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 4 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Foster City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Toma Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Toma Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.